Virulence May Determine the Necessary Duration and Dosage of Oseltamivir Treatment for Highly Pathogenic A/Vietnam/1203/04 Influenza Virus in Mice
BackgroundControl of highly pathogenic avian H5N1 influenza viruses is a major public-health concern. Antiviral drugs could be the only option early in the pandemic MethodsBALB/c mice were given oseltamivir (0.1, 1, or 10 mg/kg/day) twice daily by oral gavage; the first dose was given 4 h before ino...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2005-08, Vol.192 (4), p.665-672 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 672 |
|---|---|
| container_issue | 4 |
| container_start_page | 665 |
| container_title | The Journal of infectious diseases |
| container_volume | 192 |
| creator | Yen, Hui-Ling Monto, Arnold S. Webster, Robert G. Govorkova, Elena A. |
| description | BackgroundControl of highly pathogenic avian H5N1 influenza viruses is a major public-health concern. Antiviral drugs could be the only option early in the pandemic MethodsBALB/c mice were given oseltamivir (0.1, 1, or 10 mg/kg/day) twice daily by oral gavage; the first dose was given 4 h before inoculation with H5N1 A/Vietnam/1203/04 (VN1203/04) virus. Five- and 8-day regimens were evaluated ResultsOseltamivir produced a dose-dependent antiviral effect against VN1203/04 in vivo (P |
| doi_str_mv | 10.1086/432008 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_19277542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30086270</jstor_id><oup_id>10.1086/432008</oup_id><sourcerecordid>30086270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-9c55d1537684d51188a5d0dfc35192d362489771a996fec9b8f7a81a217ad4f03</originalsourceid><addsrcrecordid>eNp1kd1uEzEQhVcIREOBNwAZJLhb4p9d_1xWKZBKKS2oRBU3luudTVx27WB7EeUxeGI2StRISFyN5PPpzPiconhO8DuCJZ9WjGIsHxQTUjNRck7Yw2KCMaUlkUodFU9SusUYV4yLx8UR4ZhKwvik-LN0cejAW0Dn5g6dQobYOw8orwF9AgspmTi-D9FkFzwyvkGnIZkVoNCiiwRdNr376SK6imByDz6jNkQ0d6t1d4cuTV6HFXhn0cl06SB7008JxWyKK3Tm224A_9ug7REJOY_OnYWnxaPWdAme7edx8fXD-6vZvFxcfDybnSxKW1cql8rWdbP9LZdVUxMipakb3LSW1UTRhnFaSSUEMUrxFqy6ka0wkhhKhGmqFrPj4u3OdxPDjwFS1r1LFrrOeAhD0qOLEHVFR_D1P-BtGKIfb9OUMoWZpOrgZmNIKUKrN9H1Y3aaYL2tSO8qGsGXe7fhpofmgO07GYE3e8Aka7o2Gm9dOnAC0zFBMnKvdlwYNv9f9mLH3KYc4j3FRo1Tsc2g3OkuZfh1r5v4XXPBRK3n19_09WJZf5nVl_oz-wsf27ks</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223903829</pqid></control><display><type>article</type><title>Virulence May Determine the Necessary Duration and Dosage of Oseltamivir Treatment for Highly Pathogenic A/Vietnam/1203/04 Influenza Virus in Mice</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Yen, Hui-Ling ; Monto, Arnold S. ; Webster, Robert G. ; Govorkova, Elena A.</creator><creatorcontrib>Yen, Hui-Ling ; Monto, Arnold S. ; Webster, Robert G. ; Govorkova, Elena A.</creatorcontrib><description>BackgroundControl of highly pathogenic avian H5N1 influenza viruses is a major public-health concern. Antiviral drugs could be the only option early in the pandemic MethodsBALB/c mice were given oseltamivir (0.1, 1, or 10 mg/kg/day) twice daily by oral gavage; the first dose was given 4 h before inoculation with H5N1 A/Vietnam/1203/04 (VN1203/04) virus. Five- and 8-day regimens were evaluated ResultsOseltamivir produced a dose-dependent antiviral effect against VN1203/04 in vivo (P<.01). The 5-day regimen at 10 mg/kg/day protected 50% of mice; deaths in this treatment group were delayed and indicated the replication of residual virus after the completion of treatment. Eight-day regimens improved oseltamivir efficacy, and dosages of 1 and 10 mg/kg/day significantly reduced virus titers in organs and provided 60% and 80% survival rates, respectively (P<.05). Overall, the efficacy of the 5- and 8-day regimens differed significantly (death hazard ratio, 2.658; P<.01). The new H5N1 antigenic variant VN1203/04 was more pathogenic in mice than was A/HK/156/97 virus, and a prolonged and higher-dose oseltamivir regimen may be required for the most beneficial antiviral effect ConclusionsOseltamivir prophylaxis is efficacious against lethal challenge with VN1203/04 virus in mice. Viral virulence may affect the antiviral treatment schedule</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1086/432008</identifier><identifier>PMID: 16028136</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Acetamides - administration & dosage ; Animals ; Antiviral Agents - administration & dosage ; Antivirals ; Biological and medical sciences ; Brain - virology ; Cell Line ; Dosage ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Fundamental and applied biological sciences. Psychology ; Guanidines ; H5N1 subtype influenza A virus ; Infectious diseases ; Influenza A virus ; Influenza A virus - drug effects ; Influenza A virus - pathogenicity ; Influenza virus ; Inhibitory Concentration 50 ; Inoculation ; Lung - virology ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Microbiology ; Miscellaneous ; Orthomyxoviridae ; Orthomyxoviridae Infections - drug therapy ; Oseltamivir ; Placebos ; Pyrans ; Sialic Acids - pharmacology ; Virology ; Virulence ; Virus Replication - drug effects ; Viruses ; Zanamivir</subject><ispartof>The Journal of infectious diseases, 2005-08, Vol.192 (4), p.665-672</ispartof><rights>Copyright 2005 Infectious Diseases Society of America</rights><rights>2005 by the Infectious Diseases Society of America 2005</rights><rights>2005 INIST-CNRS</rights><rights>Copyright University of Chicago Press Aug 15, 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-9c55d1537684d51188a5d0dfc35192d362489771a996fec9b8f7a81a217ad4f03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30086270$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30086270$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17021201$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16028136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yen, Hui-Ling</creatorcontrib><creatorcontrib>Monto, Arnold S.</creatorcontrib><creatorcontrib>Webster, Robert G.</creatorcontrib><creatorcontrib>Govorkova, Elena A.</creatorcontrib><title>Virulence May Determine the Necessary Duration and Dosage of Oseltamivir Treatment for Highly Pathogenic A/Vietnam/1203/04 Influenza Virus in Mice</title><title>The Journal of infectious diseases</title><addtitle>The Journal of Infectious Diseases</addtitle><addtitle>The Journal of Infectious Diseases</addtitle><description>BackgroundControl of highly pathogenic avian H5N1 influenza viruses is a major public-health concern. Antiviral drugs could be the only option early in the pandemic MethodsBALB/c mice were given oseltamivir (0.1, 1, or 10 mg/kg/day) twice daily by oral gavage; the first dose was given 4 h before inoculation with H5N1 A/Vietnam/1203/04 (VN1203/04) virus. Five- and 8-day regimens were evaluated ResultsOseltamivir produced a dose-dependent antiviral effect against VN1203/04 in vivo (P<.01). The 5-day regimen at 10 mg/kg/day protected 50% of mice; deaths in this treatment group were delayed and indicated the replication of residual virus after the completion of treatment. Eight-day regimens improved oseltamivir efficacy, and dosages of 1 and 10 mg/kg/day significantly reduced virus titers in organs and provided 60% and 80% survival rates, respectively (P<.05). Overall, the efficacy of the 5- and 8-day regimens differed significantly (death hazard ratio, 2.658; P<.01). The new H5N1 antigenic variant VN1203/04 was more pathogenic in mice than was A/HK/156/97 virus, and a prolonged and higher-dose oseltamivir regimen may be required for the most beneficial antiviral effect ConclusionsOseltamivir prophylaxis is efficacious against lethal challenge with VN1203/04 virus in mice. Viral virulence may affect the antiviral treatment schedule</description><subject>Acetamides - administration & dosage</subject><subject>Animals</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antivirals</subject><subject>Biological and medical sciences</subject><subject>Brain - virology</subject><subject>Cell Line</subject><subject>Dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Guanidines</subject><subject>H5N1 subtype influenza A virus</subject><subject>Infectious diseases</subject><subject>Influenza A virus</subject><subject>Influenza A virus - drug effects</subject><subject>Influenza A virus - pathogenicity</subject><subject>Influenza virus</subject><subject>Inhibitory Concentration 50</subject><subject>Inoculation</subject><subject>Lung - virology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Orthomyxoviridae</subject><subject>Orthomyxoviridae Infections - drug therapy</subject><subject>Oseltamivir</subject><subject>Placebos</subject><subject>Pyrans</subject><subject>Sialic Acids - pharmacology</subject><subject>Virology</subject><subject>Virulence</subject><subject>Virus Replication - drug effects</subject><subject>Viruses</subject><subject>Zanamivir</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kd1uEzEQhVcIREOBNwAZJLhb4p9d_1xWKZBKKS2oRBU3luudTVx27WB7EeUxeGI2StRISFyN5PPpzPiconhO8DuCJZ9WjGIsHxQTUjNRck7Yw2KCMaUlkUodFU9SusUYV4yLx8UR4ZhKwvik-LN0cejAW0Dn5g6dQobYOw8orwF9AgspmTi-D9FkFzwyvkGnIZkVoNCiiwRdNr376SK6imByDz6jNkQ0d6t1d4cuTV6HFXhn0cl06SB7008JxWyKK3Tm224A_9ug7REJOY_OnYWnxaPWdAme7edx8fXD-6vZvFxcfDybnSxKW1cql8rWdbP9LZdVUxMipakb3LSW1UTRhnFaSSUEMUrxFqy6ka0wkhhKhGmqFrPj4u3OdxPDjwFS1r1LFrrOeAhD0qOLEHVFR_D1P-BtGKIfb9OUMoWZpOrgZmNIKUKrN9H1Y3aaYL2tSO8qGsGXe7fhpofmgO07GYE3e8Aka7o2Gm9dOnAC0zFBMnKvdlwYNv9f9mLH3KYc4j3FRo1Tsc2g3OkuZfh1r5v4XXPBRK3n19_09WJZf5nVl_oz-wsf27ks</recordid><startdate>20050815</startdate><enddate>20050815</enddate><creator>Yen, Hui-Ling</creator><creator>Monto, Arnold S.</creator><creator>Webster, Robert G.</creator><creator>Govorkova, Elena A.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20050815</creationdate><title>Virulence May Determine the Necessary Duration and Dosage of Oseltamivir Treatment for Highly Pathogenic A/Vietnam/1203/04 Influenza Virus in Mice</title><author>Yen, Hui-Ling ; Monto, Arnold S. ; Webster, Robert G. ; Govorkova, Elena A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-9c55d1537684d51188a5d0dfc35192d362489771a996fec9b8f7a81a217ad4f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Acetamides - administration & dosage</topic><topic>Animals</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antivirals</topic><topic>Biological and medical sciences</topic><topic>Brain - virology</topic><topic>Cell Line</topic><topic>Dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Guanidines</topic><topic>H5N1 subtype influenza A virus</topic><topic>Infectious diseases</topic><topic>Influenza A virus</topic><topic>Influenza A virus - drug effects</topic><topic>Influenza A virus - pathogenicity</topic><topic>Influenza virus</topic><topic>Inhibitory Concentration 50</topic><topic>Inoculation</topic><topic>Lung - virology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Orthomyxoviridae</topic><topic>Orthomyxoviridae Infections - drug therapy</topic><topic>Oseltamivir</topic><topic>Placebos</topic><topic>Pyrans</topic><topic>Sialic Acids - pharmacology</topic><topic>Virology</topic><topic>Virulence</topic><topic>Virus Replication - drug effects</topic><topic>Viruses</topic><topic>Zanamivir</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yen, Hui-Ling</creatorcontrib><creatorcontrib>Monto, Arnold S.</creatorcontrib><creatorcontrib>Webster, Robert G.</creatorcontrib><creatorcontrib>Govorkova, Elena A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yen, Hui-Ling</au><au>Monto, Arnold S.</au><au>Webster, Robert G.</au><au>Govorkova, Elena A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Virulence May Determine the Necessary Duration and Dosage of Oseltamivir Treatment for Highly Pathogenic A/Vietnam/1203/04 Influenza Virus in Mice</atitle><jtitle>The Journal of infectious diseases</jtitle><stitle>The Journal of Infectious Diseases</stitle><addtitle>The Journal of Infectious Diseases</addtitle><date>2005-08-15</date><risdate>2005</risdate><volume>192</volume><issue>4</issue><spage>665</spage><epage>672</epage><pages>665-672</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>BackgroundControl of highly pathogenic avian H5N1 influenza viruses is a major public-health concern. Antiviral drugs could be the only option early in the pandemic MethodsBALB/c mice were given oseltamivir (0.1, 1, or 10 mg/kg/day) twice daily by oral gavage; the first dose was given 4 h before inoculation with H5N1 A/Vietnam/1203/04 (VN1203/04) virus. Five- and 8-day regimens were evaluated ResultsOseltamivir produced a dose-dependent antiviral effect against VN1203/04 in vivo (P<.01). The 5-day regimen at 10 mg/kg/day protected 50% of mice; deaths in this treatment group were delayed and indicated the replication of residual virus after the completion of treatment. Eight-day regimens improved oseltamivir efficacy, and dosages of 1 and 10 mg/kg/day significantly reduced virus titers in organs and provided 60% and 80% survival rates, respectively (P<.05). Overall, the efficacy of the 5- and 8-day regimens differed significantly (death hazard ratio, 2.658; P<.01). The new H5N1 antigenic variant VN1203/04 was more pathogenic in mice than was A/HK/156/97 virus, and a prolonged and higher-dose oseltamivir regimen may be required for the most beneficial antiviral effect ConclusionsOseltamivir prophylaxis is efficacious against lethal challenge with VN1203/04 virus in mice. Viral virulence may affect the antiviral treatment schedule</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>16028136</pmid><doi>10.1086/432008</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2005-08, Vol.192 (4), p.665-672 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19277542 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Acetamides - administration & dosage Animals Antiviral Agents - administration & dosage Antivirals Biological and medical sciences Brain - virology Cell Line Dosage Dose-Response Relationship, Drug Drug Administration Schedule Female Fundamental and applied biological sciences. Psychology Guanidines H5N1 subtype influenza A virus Infectious diseases Influenza A virus Influenza A virus - drug effects Influenza A virus - pathogenicity Influenza virus Inhibitory Concentration 50 Inoculation Lung - virology Medical sciences Mice Mice, Inbred BALB C Microbiology Miscellaneous Orthomyxoviridae Orthomyxoviridae Infections - drug therapy Oseltamivir Placebos Pyrans Sialic Acids - pharmacology Virology Virulence Virus Replication - drug effects Viruses Zanamivir |
| title | Virulence May Determine the Necessary Duration and Dosage of Oseltamivir Treatment for Highly Pathogenic A/Vietnam/1203/04 Influenza Virus in Mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A44%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Virulence%20May%20Determine%20the%20Necessary%20Duration%20and%20Dosage%20of%20Oseltamivir%20Treatment%20for%20Highly%20Pathogenic%20A/Vietnam/1203/04%20Influenza%20Virus%20in%20Mice&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Yen,%20Hui-Ling&rft.date=2005-08-15&rft.volume=192&rft.issue=4&rft.spage=665&rft.epage=672&rft.pages=665-672&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1086/432008&rft_dat=%3Cjstor_proqu%3E30086270%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223903829&rft_id=info:pmid/16028136&rft_jstor_id=30086270&rft_oup_id=10.1086/432008&rfr_iscdi=true |